For injection: 100 mg of lyophilized infliximab-abda …

1 1 HIGHLIGHTS OF prescribing information These highlights do not include all the information needed to use RENFLEXIS safely and effectively. See full prescribing information for RENFLEXIS. RENFLEXIS ( infliximab-abda ) for injection, for intravenous use Initial Approval: 2017 RENFLEXIS ( infliximab-abda ) is biosimilar* to REMICADE (infliximab). (1) WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. Discontinue RENFLEXIS if a patient develops a serious infection.

2 Perform test for latent TB; if positive, start treatment for TB prior to starting RENFLEXIS. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( ) Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers including infliximab products. Almost all had received azathioprine or 6- mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. The majority of cases were reported in patients with Crohn s disease or ulcerative colitis, most of whom were adolescent or young adult males.

3 ( ) ---------------------------RECENT MAJOR CHANGES-------------------------- Warnings and Precautions: Malignancies ( ) 3/2019 Warnings and Precautions: Cardiovascular and Cerebrovascular Reactions During and After Infusion ( ) 3/2019 ---------------------------INDICATIONS AND USAGE--------------------------- RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn s Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.

4 ( ) Pediatric Crohn s Disease: reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( ) Ulcerative Colitis: reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( ) Rheumatoid Arthritis in combination with methotrexate: reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( ) Ankylosing Spondylitis: reducing signs and symptoms in patients with active disease.

5 ( ) Psoriatic Arthritis: reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( ) Plaque Psoriasis: treatment of adult patients with chronic severe ( , extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( ) -----------------------DOSAGE AND ADMINISTRATION ---------------------- RENFLEXIS is administered by intravenous infusion over a period of not less than 2 hours. ( ) Crohn s Disease 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some adult patients who initially respond to treatment may benefit from increasing the dose to 10 mg/kg if they later lose their response.

6 ( ) Pediatric Crohn s Disease 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. ( ) Ulcerative Colitis 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. ( ) Rheumatoid Arthritis In conjunction with methotrexate, 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some patients may benefit from increasing the dose up to 10 mg/kg or treating as often as every 4 weeks. ( ) Ankylosing Spondylitis 5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks. ( ) Psoriatic Arthritis and Plaque Psoriasis 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. ( ) and ( ) ----------------------DOSAGE FORMS AND STRENGTHS -------------------- For injection: 100 mg of lyophilized infliximab-abda in a 20 mL vial for intravenous infusion. (3) ------------------------------CONTRAINDI CATIONS ------------------------------ RENFLEXIS doses >5 mg/kg in moderate to severe heart failure.

7 (4) Previous severe hypersensitivity reaction to infliximab products or known hypersensitivity to inactive components of RENFLEXIS or to any murine proteins. (4) ------------------------WARNINGS AND PRECAUTIONS ---------------------- Serious infections do not give RENFLEXIS during an active infection. If an infection develops, monitor carefully and stop RENFLEXIS if infection becomes serious. ( ) Invasive fungal infections for patients who develop a systemic illness on RENFLEXIS, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic ( ) Malignancies the incidence of malignancies, including invasive cervical cancer and lymphoma, was greater in TNF blocker treated patients than in controls.

8 Due to the risk of HSTCL carefully assess the risk/benefit especially if the patient has Crohn s disease or ulcerative colitis, is male, and is receiving azathioprine or 6-mercaptopurine treatment. ( ) Hepatitis B virus reactivation test for HBV infection before starting RENFLEXIS. Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop RENFLEXIS and begin anti-viral therapy. ( ) Hepatotoxicity severe hepatic reactions, some fatal or necessitating liver transplantation. Stop RENFLEXIS in cases of jaundice and/or marked liver enzyme elevations. ( ) Heart failure new onset or worsening symptoms may occur. (4, ) Cytopenias advise patients to seek immediate medical attention if signs and symptoms develop, and consider stopping RENFLEXIS.

9 ( ) Hypersensitivity serious infusion reactions including anaphylaxis or serum sickness-like reactions may occur. ( ) Cardiovascular and Cerebrovascular Reactions Cerebrovascular accidents, myocardial infarctions (some fatal), and arrhythmias have been reported during and within 24 hours of initiation of RENFLEXIS infusion. Monitor patients during RENFLEXIS infusion and if serious reaction occurs, discontinue infusion. ( ) Demyelinating disease exacerbation or new onset may occur. ( ) Lupus-like syndrome stop RENFLEXIS if syndrome develops. ( ) Live vaccines or therapeutic infectious agents should not be given with RENFLEXIS. Bring pediatric patients up to date with all vaccinations prior to initiating RENFLEXIS.

10 At least a six month waiting period following birth is recommended before the administration of live vaccines to infants exposed in utero to infliximab products ( ) ------------------------------ADVERSE REACTIONS------------------------------ Most common adverse reactions (>10%) infections ( upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain. ( ) To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA1088 or -------------------------------DRUG INTERACTIONS---------------------------- -- Use with anakinra or abatacept increased risk of serious infections ( ) ------------------------USE IN SPECIFIC POPULATIONS----------------------- Pediatric Use Infliximab products have not been studied in children with Crohn s disease or ulcerative colitis <6 years of age.